Skip to main content
Clinical Trials/NCT06178510
NCT06178510
Recruiting
N/A

POStoperative INTELLiVENT-adaptive Support VEntilation in Cardiac Surgery Patients II (POSITiVE II) - a Randomized Clinical Trial

Medical University of Vienna1 site in 1 country328 target enrollmentMay 31, 2024
ConditionsVentilator Lung

Overview

Phase
N/A
Intervention
Not specified
Conditions
Ventilator Lung
Sponsor
Medical University of Vienna
Enrollment
328
Locations
1
Primary Endpoint
Quality of ventilation
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

'POStoperative INTELLiVENT-adaptive support VEntilation in cardiac surgery patients II (POSITiVE II) is an investigator-initiated, international, multicenter, parallel, randomized clinical trial in patients after cardiac surgery.

Detailed Description

To compare INTELLiVENT-ASV with conventional ventilation with respect to (i.) quality of ventilation; and (ii.) ICU nursing staff workload in an international cohort of participants receiving postoperative ventilation after cardiac surgery. This study will also determine the effects of INTELLiVENT-ASV on clinical outcomes, including (iii.) duration of postoperative ventilation and (iv.) length of stay in ICU.

Registry
clinicaltrials.gov
Start Date
May 31, 2024
End Date
December 2025
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Prof. Dr. Edda Tschernko

Principal Investigator

Medical University of Vienna

Eligibility Criteria

Inclusion Criteria

  • aged \> 18 years of age;
  • scheduled for elective cardiac surgery; and
  • expected to receive postoperative ventilation in the ICU for \> 2 hours.

Exclusion Criteria

  • any emergency or semi-elective surgery (precluding informed written consent);
  • any surgery other than CABG, valve replacement or repair, or a combination (i.e., patients planned for surgery for congenital heart disease, or scheduled for heart transplantation are excluded);
  • enrolled in another interventional trail;
  • no written informed consent obtained;
  • history of recent pneumectomy or lobectomy;
  • history of COPD with oxygen at home;
  • body mass index \> 35;
  • preoperative forced expiratory volume in the first second (FeV1)/forced vital capacity (VC) \< 50% (if available);
  • preoperative arterial oxygen partial pressure (PaO2) \< 60 mm Hg (at room air);
  • preoperative arterial carbon dioxide partial pressure (PaCO2) \> 50 mm Hg;

Outcomes

Primary Outcomes

Quality of ventilation

Time Frame: During the first 2 hours, since admission on the ICU with the start of the intervention ventilation mode.

The primary outcome is quality of ventilation, which is the proportion of time spent in three predefined and previously used zones of ventilation in the first 2 hours of postoperative ventilation. * An optimal zone = Tidal volume (TV) = 4-8 ml/kg of the predicted body weight (PBW) with an EtCO2 = 30-45mmHg, a plateau pressure = \<31cmH2O and SpO2 = 93-98%. * An acceptable zone = TV = 8-12 ml/kg of PBW with an EtCO2 = 25-30 or 45-50mmHg, a plateau pressure = 31-35 cmH2O and SpO2 = 85-93% or \>98%. * An unacceptable zone = TV \>12 ml/kg of PBW or an EtCO2 = \<25 or \>50mmHg, plateau pressure \>35 cmH2O or SpO2 = \<85%.

Secondary Outcomes

  • Proportion of breath spent in zones of ventilation(Up to 6 hours of mechanical ventilation time)
  • ICU nursing staff workload(24 hours)
  • Patient-ventilator asynchrony(Up to 6 hours of mechanical ventilation time)
  • ICU length of stay(From date of ICU admission until the date of ICU discharge, assessed up to 30 days)
  • Hospital length of stay(From date of hospital admission until the date of hospital discharge, assessed up to 30 days)
  • Duration of postoperative ventilation(8 hours or until extubation)
  • Mortality(28-day)

Study Sites (1)

Loading locations...

Similar Trials